WAT

Waters Corporation (WAT) - Form 8-K Summary

Business Context and Reporting Period

This Current Report on Form 8-K, dated January 16, 2026, concerns Waters Corporation's ongoing Reverse Morris Trust transaction with Becton, Dickinson and Company (BD). The filing provides supplemental disclosures to the definitive proxy statement/prospectus following shareholder litigation and demand letters alleging omitted material information. A special meeting of Waters' stockholders is scheduled for January 27, 2026, to vote on the merger of BD's Biosciences and Diagnostic Solutions business (SpinCo) into Waters.

Key Financial Metrics and Projections

The filing contains unaudited prospective financial information for Waters, SpinCo, and the combined entity, extending through 2034. These figures are estimates and not historical results.

Note: The filing does not provide current period historical revenue, profit, or cash flow for Waters or BD. It only provides forward-looking projections.

Material Changes and Supplemental Disclosures

In response to litigation, Waters voluntarily supplemented disclosures regarding the negotiation timeline and valuation analysis:

• Negotiation Timeline: Clarified that Waters' board discussed M&A opportunities in February 2025. A preliminary non-binding proposal was submitted to BD on March 5, 2025. Crucially, the filing states that no discussions regarding post-closing employment arrangements for BD management or specific director designations occurred prior to the execution of the Merger Agreement on July 13, 2025.
• Valuation Analysis: Barclays' Discounted Cash Flow (DCF) analysis implied an equity value range for Waters of $20.9 billion to $24.7 billion ($348.11 to $410.57 per share) as of July 11, 2025. The BDS Business was valued between $16.8 billion and $19.7 billion on a stand-alone basis, rising to $19.6 billion to $23.1 billion when including expected synergies.
• Broker Targets: The median broker target price for Waters common stock was approximately $375.00, with a range of $350.00 to $460.00.

Guidance, Risks, and Contingencies

Management Commentary: The Waters Board unanimously recommends a "FOR" vote on the merger proposals. Management asserts that the disclosures in the proxy statement comply with all applicable laws and denies any culpability regarding the litigation claims.

Risks and Contingencies:

• Litigation: Two lawsuits and demand letters allege the proxy statement omitted material information. Waters is supplementing disclosures to moot these claims and avoid delays.
• Transaction Completion: Risks include failure to satisfy closing conditions, regulatory approvals, or obtaining the required stockholder vote.
• Integration and Synergies: Uncertainty regarding the ability to realize anticipated revenue and cost synergies or to integrate the businesses effectively.
• Forward-Looking Statements: All financial projections are subject to significant risks and uncertainties, including economic conditions, regulatory changes, and the potential for the transaction not to close.

Key Facts for Investor Verification

• Vote Date: Confirm the outcome of the special stockholder meeting scheduled for January 27, 2026.
• Regulatory Approval: Monitor for any delays or conditions imposed by governmental entities regarding the merger.
• Employment Agreements: Verify the final terms of post-closing employment arrangements for BD management, which were not discussed prior to the Merger Agreement.
• Valuation Assumptions: Review the specific assumptions used in the DCF analysis (discount rates of 9.0%-10.0% and terminal multiples of 16.0x-18.0x) to assess the robustness of the valuation.
• Legal Status: Track the status of the shareholder lawsuits (Ryan Carroll v. Waters Corporation and Joseph Clark v. Waters Corporation) to ensure they do not impede the transaction.